Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues. …
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
New Stories
-
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials
December 1, 2025 - - Australian Biotech -
Australian company reports high response rate in trial of off-the-shelf CAR-T therapy
December 1, 2025 - -
Melbourne showcases its health and biomedical strength as leaders gather for National Precincts Summit
December 1, 2025 - - Australian Biotech -
Pharmac to expand emergency medicine access for rural and remote communities
December 1, 2025 - - Latest News -
Tetratherix joint venture secures Alcon partnership to accelerate ophthalmic biomaterials
December 1, 2025 - - Australian Biotech -
MSD to bring vaccine distribution back in-house after 40-year partnership
December 1, 2025 - - Latest News -
New PBS listing offers fresh hope for Australians living with debilitating skin condition
December 1, 2025 - - Latest News